• Market Capitalisation market-capitalisation-info ₹1,278 Cr
  • Price to Earnings Ratio price-to-earning 41.59
  • 12 Month Earnings monthly-earning ₹31 Cr

Beta Drugs Ltd. Share Price


As on 11-Dec-2023 IST


  • Prev Close info


  • Day's Openinfo


  • Today's Highinfo


  • Today's Lowinfo


  • Today's Volumeinfo


  • 52 Week rangeinfo

    ₹600.00 - 1,450.00

Please wait...

Beta Drugs Ltd. Stock Performance

1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Beta Drugs
87.19 14.42 27.30 93.99 126.48 78.96 --
S&P BSE Healthcare
31.20 4.56 6.86 29.26 12.69 17.58 12.19
S&P BSE Small Cap
43.10 7.86 8.17 40.04 33.33 24.49 20.90
As on 11-Dec-2023
Beta Drugs
10.89 436.67 58.95 -0.78 -59.74
S&P BSE Small Cap
-1.80 62.77 32.11 -6.85 -23.41
S&P BSE Healthcare
-12.10 20.87 61.45 -3.55 -5.89


Peer Median
Please wait...

Growth & Efficiency

Peer Median
Please wait...


Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Beta Drugs Ltd. Peer Comparison

    Please wait...

    Valuation Chart of Beta Drugs Ltd.

      Please wait...
        Please wait...


        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        News & Analysis of Beta Drugs Ltd.

        No Review & Analysis are available.

        Other details of Beta Drugs Ltd.




        Rahul Batra

        Managing Director

        Rahul Batra


        Baddi, Himachal Pradesh

        FAQs for Beta Drugs Ltd.

        The total asset value of Beta Drugs Ltd. stood at ₹ 205 Cr as on 31-Mar-23

        The share price of Beta Drugs Ltd. is ₹1,329.05 (NSE) as of 11-Dec-2023 IST. Beta Drugs Ltd. has given a return of 126.48% in the last 3 years.

        Beta Drugs Ltd. has a market capitalisation of ₹ 1,278 Cr as on 11-Dec-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Beta Drugs Ltd. is 10.40 times as on 11-Dec-2023, a 1.93% premium to its peers’ median range of 3.55 times.

        The P/E ratio of Beta Drugs Ltd. is 41.59 times as on 11-Dec-2023, a 0.35% premium to its peers’ median range of 30.74 times.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Beta Drugs Ltd. and enter the required number of quantities and click on buy to purchase the shares of Beta Drugs Ltd..

        The promoter of Beta Drugs Ltd. is Neeraj Batra. Neeraj Batra owns 65.96 per cent of the total equity. The chairman of the company is Rahul Batra , and the managing director is Rahul Batra..

        The promoters of Beta Drugs Ltd. have pledged 0% of the total equity as on Sep-23.

        Beta Drugs Ltd. Ratios
        Return on equity(%)
        Return on capital employed(%)
        Debt-to-equity ratio
        Dividend yield(%)

        Yes, TTM profit after tax of Beta Drugs Ltd. was ₹31 Cr.

        Edit peer-selector-edit
        Please wait...
        Please wait...
        Please wait...

        Review & Analysis

        No Review & Analysis are available.

        News & Announcements

        No News & Announcements are available.

        Key Facts

        • Market cap market-cap-information ₹1,277.72 Cr
        • Revenue (TTM)revenue-information ₹227.11 Cr
        • Earnings (TTM) earning-information ₹30.72 Cr
        • Cash date-information ₹19.16 Cr
        • Total Debt info ₹20.33 Cr
        • Promoters' ownership promoters_ownership 66.73%
        • Liquidity liquidity Moderate
        • 52 Week range week-range ₹600.00 - 1,450.00
        • Face value face-value ₹10.00
        • Shares outstanding share-outstanding 96,13,790
        • 10 Years Aggregate:

          CFO: ₹103.21 Cr

          EBITDA: ₹170.23 Cr

          Net Profit: ₹96.80 Cr

        About The Company

        • Incorporated 2005
        • Chairman Rahul Batra
        • Managing Director Rahul Batra
        • Listing key-listing NSE: BETA
        • Country India
        • Headquarters headquarters Baddi, Himachal Pradesh
        • Website website www.betadrugslimited.com
        • Business


        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free

        What can Value Research do for you?

        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.